Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer.
Androgen deprivation has been associated with a wide range of iatrogenic effects impacting a variety of body systems including metabolic, musculoskeletal, cardiovascular, neurocognitive, and sexual. This review aims to provide the radiation oncology community with the knowledge to monitor and manage androgen deprivation therapy toxicity in an effort to provide the highest level of care for patients and to minimize the iatrogenic effects of androgen deprivation as much as possible.
Written by:
Johnson ME, Buyyounouski MK. Are you the author?
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Reference: Prostate Cancer. 2012;2012:580306.
doi: 10.1155/2012/580306
PubMed Abstract
PMID: 23326671
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Prostate Cancer Section
